Inhibition of glycosphingolipid biosynthesis in vitro was shown to normalize glycosphingolipid metabolism, to correct CD4+ T-cell signalling and functional abnormalities and to decrease anti-dsDNA antibody production by autologous B cells in SLE patients [46]. The gene discussed is CD4; the disease is systemic lupus erythematosus.